Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 known ✓ | P05106 | 4/20 | 0.57 |
| ▸ | ITGA2B known ✓ | P08514 | 4/20 | 0.57 |
| ▸ | DPP4 known ✓ | P27487 | 2/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.64 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.60 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.56 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.56 |
| ▸ | TLR2 | O60603 | 2/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.55 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.55 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.55 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.55 |
| ▸ | ECE1 | P42892 | 1/20 | 0.55 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.53 |
| ▸ | CPB1 | P15086 | 1/20 | 0.53 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3176226 | 1.00 | CTSL (0.64) | CTSLSIRT2ITGB3ITGA2BSIRT1 | |
| SCHEMBL3251534 | 0.99 | CTSL (0.65) | CTSLSIRT2ITGB3ITGA2BSIRT1 | |
| SCHEMBL3251530 | 0.99 | CTSL (0.65) | CTSLSIRT2ITGB3ITGA2BSIRT1 | |
| SCHEMBL7792804 | 0.95 | CTSL (0.66) | CTSLSIRT2ITGB3ITGA2BSIRT1 | |
| SCHEMBL7792802 | 0.95 | CTSL (0.66) | CTSLSIRT2ITGB3ITGA2BSIRT1 | |
| Hydrochloric Acid SCHEMBL4994643 | 0.91 | ITGB3 (0.65) | SIRT2ITGB3ITGA2BSIRT1SIRT3 | |
| Hydrochloric Acid SCHEMBL21219335 | 0.91 | ITGB3 (0.65) | SIRT2ITGB3ITGA2BSIRT1SIRT3 | |
| Hydrochloric Acid SCHEMBL11310715 | 0.91 | ITGB3 (0.65) | SIRT2ITGB3ITGA2BSIRT1SIRT3 | |
| Hydrochloric Acid SCHEMBL7284342 | 0.91 | ITGB3 (0.58) | CTSLSIRT2ITGB3ITGA2BSIRT1 | |
| Hydrochloric Acid SCHEMBL7284348 | 0.91 | ITGB3 (0.58) | CTSLSIRT2ITGB3ITGA2BSIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1544208-B1 | PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | KISSEI PHARMACEUTICAL (JP) | 2010-05-26 | — | — | EP | disclosed |
| US-7655632-B2 | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-02-02 | — | — | US | disclosed |
| US-20080312153-A1 | PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-7375087-B2 | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-05-20 | — | — | US | disclosed |
| CN-100351263-C | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL COMPANY (JP) | 2007-11-28 | — | — | CN | disclosed |
| US-20060166899-A1 | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-07-27 | — | — | US | disclosed |
| CN-1688596-A | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL COMPANY (JP) | 2005-10-26 | — | — | CN | disclosed |
| EP-1544208-A1 | PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2005-06-22 | — | — | EP | disclosed |
| US-5942493-A | LH-RH antagonists having improved action | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1999-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166899-A1 | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | SLC5A1, SLC5A2, SULT2A1 | ITGB3 2225/4885ITGA2B 4090/4885DPP4 76/4885 |
| US-20080312153-A1 | PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | SLC5A1, SLC5A2, SULT2A1 | ITGB3 2225/4885ITGA2B 4090/4885DPP4 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.